Literature DB >> 28274975

Deflazacort approved for Duchenne muscular dystrophy.

Kate Traynor.   

Abstract

Entities:  

Year:  2017        PMID： 28274975     DOI： 10.2146/news170020

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  5 in total

1.  Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy.

Authors:  Ilene L Hollin; Holly Peay; Ryan Fischer; Ellen M Janssen; John F P Bridges
Journal:  Qual Life Res       Date:  2018-05-26       Impact factor: 4.147

2.  Contrast-Enhanced Near-Infrared Optical Imaging Detects Exacerbation and Amelioration of Murine Muscular Dystrophy.

Authors:  Stephen M Chrzanowski; Ravneet S Vohra; Brittany A Lee-McMullen; Abhinandan Batra; Ray A Spradlin; Jazmine Morales; Sean Forbes; Krista Vandenborne; Elisabeth R Barton; Glenn A Walter
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

3.  Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents.

Authors:  Holly Landrum Peay; Ryan Fischer; Janice P Tzeng; Sharon E Hesterlee; Carl Morris; Amy Strong Martin; Colin Rensch; Edward Smith; Valeria Ricotti; Katherine Beaverson; Hannah Wand; Carol Mansfield
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

4.  Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients.

Authors:  Ryan S Paquin; Ryan Fischer; Carol Mansfield; Brennan Mange; Katherine Beaverson; Annie Ganot; Amy Strong Martin; Carl Morris; Colin Rensch; Valeria Ricotti; Leo J Russo; Alesia Sadosky; Edward C Smith; Holly L Peay
Journal:  Orphanet J Rare Dis       Date:  2019-05-09       Impact factor: 4.123

5.  Expeditious synthesis and preliminary antimicrobial activity of deflazacort and its precursors.

Authors:  Anna Esposito; Eliana De Gregorio; Maria De Fenza; Daniele D'Alonzo; Anil Satawani; Annalisa Guaragna
Journal:  RSC Adv       Date:  2019-07-10       Impact factor: 4.036
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.